Medical network on April 17 - April 14, people club department issued "about 2017 national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue negotiations range of circular, sure 44 species medicine into the national health insurance directory talks. 

 

The reporter understands by state food drug safety administration website, 20 kinds of Chinese medicine, 24 kinds of imported drugs incorporated in the catalogue, these drugs mainly for major diseases such as cancer, cardiovascular disease, leukemia. In the above two kinds of Chinese medicine, A shares one of its top 10 listed companies products. 

 

A pharmaceutical industry analyst told reporters that the enterprise product support if access to health care, patients can significantly improve permeability, expand market share. 

 

The price is expected to be slashed 

 

Third-party medical service platform MaiSiKang lai founder Shi Lichen in an interview with "securities journal" reporter, said the final after the outcome of the negotiations, related drug prices is expected to be slashed. 

 

But for the enterprise, is good or bad, still to be determined. If the price cuts, and there is no corresponding increase in sales, business interests may be damaged, involved in the talks also reduces initiative. 

 

People club department released in February 2017 the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue upon receipt of the notice, will explore establishing access to health care medicine negotiation mechanism. People club department determined via expert evaluation of negotiations negotiations drugs according to the rules, eligible drugs incorporated in the medical insurance to pay limits. 

 

It is understood that the drug directory adjustment scheme is put forward for clinical curative effect is necessary, and the prices are more expensive, according to the current market price included in the catalog can bring a certain risk of fund, exclusive patent medicines, explore to establish negotiating access mechanism. After agree with the enterprise, the government will agree varieties incorporated into the scope of medical insurance fund pays. 

 

Agree on patents, exclusive drug prices are expected to have fallen sharply. Last year, the national health and family planning commission announced the first batch of national drug price negotiation results, used in the treatment of chronic hepatitis b of tenofovir ester and used in the treatment of non-small cell lung cancer ek the treatment for, three kinds of drug reduction reached 67%, 54% and 54%, respectively. 

 

But for the enterprise, whether to accept the negotiation price is another thing. Shi Lichen thinks, if the price drop is larger, and there is no corresponding increase in sales, the enthusiasm of enterprises involved in the negotiations will be reduced. "Last year with the national product has five price negotiations, but in the end to achieve consistent product only 3". 

 

About 10 listed companies 

 

According to "securities daily" reporters queries, in the above two kinds of Chinese medicines, involving a-share listed companies 10. CanYi capsule production enterprise for jilin for both pharmaceutical co., LTD., the company is honored group subsidiary. Jilin honored pharmaceutical co., LTD. In 2015 net profit of 46.98 million yuan. Blood will net injection for red sun pharmaceutical production enterprises, in 2016, the red sun pharmaceutical blood will net injection of sales of 1.124 billion yuan, the gross margin of 92.6%; Compound Huang Dai chip production enterprise for the last billion sails pharmaceutical co., LTD., the company for easy sail pharmaceutical companies. Sail pharmaceutical 2016 annual report is introduced, it is one of the few in China in the New England journal of medicine published research of traditional Chinese medicine product, is the treatment of acute early young leukemia of specific products. 

 

Injection gas after pulse (lyophilization) of manufacturing enterprises is the pride of tianjin tasly pharmaceutical co., LTD., the company is a wholly owned subsidiary of tasly. Tasly 2016 annual report shows that gas injection for reasons after vein (lyophilization) is one of the company's core products; Ginkgo diterpene lactone meglumine injection production enterprises for kang pharmaceutical fate. Kang edge pharmaceutical 2016 annual report showed that ginkgo diterpene lactone meglumine injection is one of the representative of the company product line of heart head blood-vessel varieties, last year's cardiovascular field operating income growth of 34.36% over 2015, the main department of ginkgo diterpene lactone meglumine injection drugs such as sales growth. 

 

In addition, Shenzhen Salubris Pharmaceuticals Co., ltd. of the sand of the ester, yasuhiro miyata pharmaceutical compaq heap of eye ophthalmic injection, hengrui pharmaceutical mesylate path for slice, Tibetan medicine di kang biological pharmaceutical Co., Ltd., chengdu injection with recombinant human brain natriuretic peptide, Shanghai pharmaceutical consortium biochemical pharmaceutical Co., Ltd. Of guangdong temple for injection yuri orlov kling biotechnology Co., Ltd., Shenzhen micro core in the west of the amine piece of sanofi-aventis pharmaceutical Co., Ltd., tianjin injection with astragalus polysaccharides hundred abundant pharmaceutical Co., Ltd., chengdu lactones ginkgo biloba injection and so on also entered the national health care medicine negotiation directory. 

 

According to the reporter learned through the national enterprise credit information publicity system, after have held the teda co, a subsidiary of shenzhen microchip biotechnology co., LTD. But according to the latest information, shenzhen microchip shareholders in biological information change in on April 13, 2017, teda shares no longer list. 

 

Reputation value pharmaceutical industry in 2015 and sanofi-aventis pharmaceutical co., LTD in tianjin was injected with astragalus polysaccharides (injection (sterile powder)) exclusive sales agent agreement. However, the agency agreement announced in June 2016. 

 

In addition, chengdu yulin pharmaceutical co., LTD., listed on the new three board in 2016, the company, according to data released business revenue of 511.2618 million yuan in 2016, operating profit of 75.2841 million yuan, profit of 80.3231 million yuan, attributable to shareholders of listed company net profit of 69.7509 million yuan.